Sarah Harris, PhD

Bristol Myers Squibb

Poster(s):

• P3571 - Impact of Ozanimod on Interleukin-17A Levels and the Association With OZA Efficacy in Patients With Moderately to Severely Active Ulcerative Colitis : Data From the Phase 3 True North Study
  Tuesday, October 24, 2023

  10:30 AM – 4:00 PM PT

• P3572 - Association of Nonswitched Memory B-Cell (MBC) Levels With Ozanimod (OZA) Efficacy in Patients (Pts) With Moderately to Severely Active Crohn’s Disease (CD): Results From the Phase 2 STEPSTONE Study
  Tuesday, October 24, 2023

  10:30 AM – 4:00 PM PT

• P3573 - Impact of Ozanimod on C-Reactive Protein Levels and the Association with OZA Efficacy in Patients With Moderately to Severely Active Ulcerative Colitis: Data From the Phase 3 True North Study
  Tuesday, October 24, 2023

  10:30 AM – 4:00 PM PT